Atherosclerotic cardiovascular disease remains the primary cause of morbidity and premature mortality in patients living with type 2 diabetes mellitus. Although clinicians routinely measure standard low-density lipoprotein cholesterol to guide statin therapy, standard parameters often fail to capture the complex atherogenic dyslipidemia characteristic of metabolic disease. Evaluating circulating lipid ratios in diabetes offers a practical, low-cost method to capture the balance between atherogenic particles and protective high-density lipoproteins. Consequently, investigating how these calculated indices relate to hard cardiovascular endpoints provides critical clinical insights for routine patient care.

Understanding Atherogenic Dyslipidemia and Lipid Ratios in Diabetes

Diabetic dyslipidemia encompasses a distinct triad consisting of elevated fasting and postprandial triglycerides, reduced high-density lipoprotein cholesterol, and a predominance of small, dense low-density lipoprotein particles. Because standard cholesterol panels frequently present normal or only mildly elevated low-density lipoprotein concentrations, they can obscure substantial residual vascular risk. Therefore, composite biomarkers such as the total cholesterol to high-density lipoprotein ratio, the triglyceride to high-density lipoprotein ratio, and non-high-density lipoprotein cholesterol ratios serve as robust proxies for atherogenic particle burden. Moreover, the triglyceride-glucose index combines glycemic and lipid parameters to quantify underlying insulin resistance. By integrating both pro-atherogenic and protective lipoproteins, these ratios reflect circulating vascular toxicity more effectively than isolated lipid fractions. Consequently, incorporating these markers into clinical evaluations enhances our physiological understanding of metabolic vascular injury and refines preventive cardiovascular strategies across diverse outpatient settings.

Key Findings from the Population Cohort Study

A landmark population cohort investigation utilizing primary care electronic health records from the Spanish National Health Service analyzed data from over 303,000 adults with type 2 diabetes. Researchers followed this extensive cohort for an average of 5.7 years, accumulating approximately 1.7 million person-years of observation. The primary outcome comprised a composite endpoint of all-cause mortality and hospital admissions for acute cerebrovascular events or ischemic heart disease. Using sex-stratified Weibull survival models adjusted for established clinical covariates, the investigators observed distinct U-shaped associations across all evaluated lipid ratios. Specifically, markedly elevated ratios significantly increased the likelihood of adverse cardiovascular events and overall mortality in both men and women. However, very low lipid ratios were also independently linked to heightened risk. These findings suggest that maintaining intermediate, balanced lipid intervals provides optimal vascular protection in diabetic individuals.

Sex-Specific Risk Thresholds and Vulnerability Patterns

An essential revelation from this large-scale analysis involves the noticeable sex-specific differences in cardiovascular risk cutoffs. While elevated lipid ratios drove adverse cardiovascular outcomes across both sexes, women exhibited lower risk threshold boundaries compared to men. Consequently, female patients began experiencing heightened cardiovascular vulnerability at lower ratio levels than their male counterparts. This biological discrepancy underscores the critical importance of avoiding a uniform approach to metabolic risk evaluation. Postmenopausal changes, differences in body fat distribution, and distinct hormonal influences may amplify vascular susceptibility to atherogenic dyslipidemia in women with diabetes. Therefore, clinicians must recognize these nuanced sex-specific cutoffs to prevent the underestimation of cardiovascular risk in female patients. Adjusting diagnostic vigilance according to sex ensures timely therapeutic interventions, which ultimately helps mitigate cardiovascular disparities and improves long-term outcomes.

Clinical Value of Non-Traditional Indices and the TyG Index

Beyond traditional cholesterol fractions, indices such as the triglyceride-glucose index and triglyceride-to-high-density lipoprotein ratio demonstrate exceptional clinical utility. The triglyceride-glucose index reflects peripheral and hepatic insulin resistance, bridging the pathogenic gap between impaired glucose homeostasis and vascular endothelial dysfunction. Similarly, the triglyceride to high-density lipoprotein ratio correlates closely with small dense low-density lipoprotein particle concentration and systemic arterial stiffness. Because these ratios utilize standard laboratory measurements already obtained during routine diabetes consultations, they require no additional laboratory expense or specialized equipment. Furthermore, tracking changes in these indices over time allows healthcare providers to assess the systemic effectiveness of lifestyle modifications and pharmacotherapy. Utilizing these non-traditional indices empowers physicians to detect subclinical cardiometabolic deterioration early, facilitating prompt management before catastrophic macrovascular complications develop.

Translating U-Shaped Curves into Routine Cardiometabolic Management

The discovery of U-shaped associations between lipid ratios and major cardiovascular outcomes highlights important therapeutic nuances. While hyperlipidemia undeniably accelerates atheroma formation, excessively low lipid levels often indicate severe systemic frailty, malnutrition, chronic inflammation, or advanced occult disease. Therefore, clinicians should avoid interpreting extremely low values as universally beneficial without assessing overall patient health. Instead, healthcare teams should aim to maintain patients within optimal, moderate ratio ranges through comprehensive cardiometabolic care. Structured lifestyle interventions, including Mediterranean dietary patterns, regular aerobic physical activity, and weight optimization, directly improve atherogenic ratios. Additionally, modern antidiabetic agents, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, confer favorable lipid-modifying effects alongside glycemic reduction. Combining individualized lifestyle support with evidence-based pharmacotherapy optimizes circulating lipid balance and reduces long-term macrovascular risk.

Practical Recommendations for Primary Care and Specialist Clinics

To implement these findings effectively, primary care physicians and endocrinologists should calculate and review lipid ratios alongside standard lipid profiles during annual diabetes reviews. First, clinicians should identify individuals positioned at the extreme upper and lower ends of ratio distributions to prioritize them for targeted clinical assessment. Second, physicians must apply sex-specific risk thresholds when interpreting total cholesterol to high-density lipoprotein and triglyceride-glucose values. Third, clinicians should address persistent ratio elevations by optimizing lifestyle interventions, intensifying statin therapy, and considering non-statin lipid-lowering agents when indicated. Finally, when encountering very low ratios, healthcare teams should systematically screen for underlying chronic illness, malabsorption, or progressive frailty. Adopting this structured, ratio-informed strategy refines cardiovascular risk stratification and supports personalized, high-value diabetes care across primary and tertiary healthcare settings.

Frequently Asked Questions

Why are lipid ratios more informative than single lipid values in diabetes?

Lipid ratios provide a comprehensive assessment of atherogenic balance by comparing dangerous, pro-inflammatory particles against protective high-density lipoproteins. In diabetic patients, absolute low-density lipoprotein cholesterol may appear normal despite high levels of atherogenic remnants and small dense particles. Ratios expose this hidden residual risk, offering clinicians a more accurate reflection of vascular risk and metabolic dysregulation without additional testing expenses.

What does a U-shaped risk curve mean for clinical lipid management?

A U-shaped curve indicates that both abnormally high and excessively low lipid ratios correlate with increased mortality and cardiovascular events. While high ratios reflect accelerated atherosclerosis driven by atherogenic particles, extremely low values often signal underlying systemic inflammation, malnourishment, or advanced chronic comorbidities. Consequently, clinicians should target moderate, healthy intervals rather than assuming that lower numbers are always better.

How should clinicians integrate sex-specific lipid thresholds into practice?

Clinicians must recognize that female patients with type 2 diabetes often exhibit adverse cardiovascular risk at lower lipid ratio thresholds than men. Therefore, healthcare teams should adopt lower trigger points when assessing cardiometabolic risk in women. Recognizing these sex differences ensures that therapeutic lifestyle adjustments and medical therapies are initiated promptly, preventing the common underdiagnosis and undertreatment of female cardiovascular disease.

Disclaimer: This content is for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Carretero-Anibarro E et al. Association of Lipid Ratios With Cardiovascular Outcomes in Type 2 Diabetes: A Population Cohort Study. Diabetes Obes Metab. 2026 Aug 17. doi: 10.1111/dom.71236. PMID: 42608333.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179-S218.